| Bioactivity | RWJ-58643 is a β-trypsin and trypsin inhibitor that is being studied for the treatment of allergic inflammatory diseases. It significantly reduces nasal allergy symptoms, eosinophil infiltration, and interleukin-5 (IL-5) levels at low doses (100 mg). However, RWJ-58643 causes late eosinophilia and elevated IL-5 levels at high doses (300 mg and 600 mg). This dose-dependent effect suggests that RWJ-58643 has potential therapeutic value in the treatment of allergic inflammation, but its use requires careful dose control. The mechanism of action of RWJ-58643 involves inhibiting β-trypsin released from mast cells, thereby regulating allergic reactions. The results of this study provide an important reference for the use of RWJ-58643 in the treatment of allergic rhinitis, but also suggest potential risks that need to be noted when using it. |
| CAS | 287183-00-0 |
| Formula | C20H26N6O4S |
| Molar Mass | 446.52 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Effects of a reversible b-tryptase and trypsin inhibitor (RWJ-58643) on nasal allergic responses |
RWJ-58643
CAS: 287183-00-0 F: C20H26N6O4S W: 446.52
RWJ-58643 is a β-trypsin and trypsin inhibitor that is being studied for the treatment of allergic inflammatory disease
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.